Subcellular fractionation was performed on human U251 glioblastoma cultures. In all subcellular fractions, the binding of the peripheral benzodiazepine ligand, [3H]PK 11195, correlated with the specific activity of monoamine oxidase (r--0.95, p < 0.001) and succinate dehydrogenase (r = 0.93, p < 0.001), two mitochondrial enzymes. The specific activity of plasma membrane and nuclear markers correlated poorly with the presence of PK 11195 binding sites. These data support the mitochondrion as the primary location of peripheral-type benzodiazepine binding sites (PBBS) in human glioma cells. Mitochondria-rich preparations were then assayed for [3H]Ro5-4964 binding. Six nM [3H]Ro5-4964 failed to specifically bind to human U251 mitochondria, but bound vigorously to mitochondria from rat C6 glioma. These data indicate that the low affinity of Ro5-4864 for PBBS in human glioma cells compared to those in rat is due to interspecies receptor variation rather than impaired drug transport into human cells.
Braestrup and Squires first demonstrated two distinct classes of benzodiazepine binding sites in rats [1, 2] . The binding sites were named the central benzodiazepine receptor (CBR) and the peripheral benzodiazepine binding site (PBBS) because of their predominance in the brain and non-CNS tissue respectively.
Although there are relatively few neuronal or glial PBBS, the receptor is abundant in glioma cells [3] [4] [5] [6] [7] . The high density of PBBS in tumors compared to normal brain parenchyma serves as the basis for positron emission tomographic (PET) imaging of human gliomas using the PBBS ligand, [llC]PK 11195 [8] . Development of improved PET ligands and ligands suitable for single photon emission computed tomography (SPECT) or radiotherapy requires an understanding of whether or not ligands must pass through tumor cell plasma membrane in order to bind to PBBS.
Defining the subcellular location of PBBS is also an essential step toward understanding the role of PBBS in cancer cells. In early studies, micromolar concentrations of PBBS ligands were shown to induce differentiation of Friend erythroleukemia cells [9] , promote melanogenesis in B16 melanoma cells [10] and inhibit proliferation of mouse thymoma cells [11] . Because the concentration of ligand required to affect cell proliferation correlated poorly with binding affinitiy, the role of PBBS in modulating tumor cell growth was subsequently questioned [12] . Recent studies have demonstrated that PBBS ligands influence tumor cells at concentrations which are consistent with receptor mediated actions. Ikezaki and Black reported that nanomolar concentrations of PK 11195 induced a modest increase in C6 rat glioma cell growth rate when the cells were grown in serum-free medium [13] . In Nb node lymphoma cells, nanomolar concentra-tions of PK 11195 and Ro5-4864 potentiate prolactin-stimulated proliferation but had no effect in the absence of prolactin [14] . PK 11195 and Ro5-4864 (10 -14 to 10-6M) also inhibit oxygen consumption of mouse C1300 neuroblastoma cells [15] .
The influence of PBBS ligands on neuroblastoma oxygen consumption supports the hypothesis that PBBS modulate mitochondrial respiration. PBBS ligands have been shown to influence mitochondrial respiration in rat kidney [16] and PBBS have been localized to mitochondria in rat kidney [17] and rat adrenal [18] . Binding sites with nearly identical drug binding parameters however, have been localized to human erythrocyte membrane preparations [19] which lack mitochondria and nuclei [20] . A nuclear location for PBBS has also been proposed, but lack of marker enzyme correlation in these studies makes it difficult to assess whether contaminants were responsible for PBBS ligand binding in the nuclear fraction [5, 21, 22] .
The current study was developed because the location of PBBS in human glioma cells cannot be extrapolated from relatively few, conflicting reports of subcellular fractionation studies in nonneoplastic rat tissues. In addition, Ro5-4864 binding was evaluated in mitochondria-rich preparations from human and rat glioma cultures. The purpose of this experiment was to determine whether the previously reported interspecies difference in PBBS affinity for Ro5-4864 and related compounds is due to receptor differences versus impaired transport of PBBS ligands into human cells [23] . 
Materials and methods

Drugs and chemicals
Cultures and tissues
Human glioblastoma line U251 was obtained from Dr. Darrel D. Bigner of Duke University. Rat glioma line C6 was purchased from American Type Culture Collection, Rockville, MD. Cultures were grown in minimum essential media supplemented with 10% fetal bovine serum at 37 ° C in humidified air supplemented with 5% CO2.
Cell disruption
All procedures were carried out at 4 ° C. Fractionation was performed on cells from eighty plates (10 cm diameter) of confluent U251 cultures which had been grown for 24-36 hours. Monolayers were washed with 4 ml 'H buffer' (5 mM HEPES, 0.21 M d-mannitol, 0.07M sucrose, 2mM benzamidine, 2 mM phenyl-methyl-sulfonyl fluoride, and 4 mM MgC12, pH = 7.4). Cells were scraped in 15 mls homogenization buffer ('H buffer' supplemented with 0.2% Nonidet P-40) then ruptured in a Dounce glass homogenizer using 15 strokes with a Type B pestle. Homogenates were spun at 200 g for 1 min. The pellet, consisting of cells which were resistant to rupture in homogenization buffer, was rehomogenized in 4 ml hypotonic homogenization buffer (diluted 4 x with distilled water). The homogenates were combined and centrifuged at 200 g for lmin. Supernatants were strained through 3 layers of gauze. The resulting slurry was designated as the 'homogenate' referred to throughout this paper.
Fractionation
Two ml of homogenate were reserved for marker assays. The remaining homogenate was centrifuged at 600 g for 20 rain. The resulting pellet was designated '0.6K'. The supernatant was centrifuged at 15,000 g for 20 min. The pellet was gently ground into a paste using an ice-filled test tube. The paste was layered over 3ml of 1M sucrose and centrifuged for 3 hrs at 40,000 g. The heavy fraction which passed through the sucrose cushion was designated '15K Hv' and the light membranes which remained on top of the cushion were designated as '15K Lt'. The supernatant from the 15,000 g spin was centrifuged at 100,000 g for 1 hr. The subsequent pellet was designated '100K' and the solution which failed to pellet at 100,000 g was designated as 'Sol'.
Enzyme assay
Clorgyline-sensitive monoamine oxidase was quantitated using [14C]tyramine as the substrate according to the method of Wurtman and Axelrod [24] . One percent bovine serum albumin was included in the assay mixture to stabilize monoamine oxidase activity.
Spectrophotometric assays were measured in a Perkin-Elmer Lambda 3 Spectrophotometer. Succinate dehydrogenase activity was determined by measuring the absorption of reduced imidazolium nitro-tetrazolium violet (INT), extracted in ethyl acetate, at 490nm [25] . Alkaline phosphatase activity was determined by measuring the liberation of p-nitrophenol from p-nitrophenylphosphate at 420 nm as previously described [26] .
DNA and protein assays
DNA was quantitated fluorimetrically using 370nm excitation and 440nm emission wavelengths in a Perkin Elmer Fluorimeter. Samples were briefly sonicated before the addition of Hoechst dye (butamamide) [27] . Calf thymus DNA was used for the standard curve in each experiment. Protein concentrations were determined by the Bradford assay (Biorad, Richmond, CA). Bovine serum albumin was used for standards.
Binding assays
Samples were incubated for 60min at 4°C with 6 nM [3H]PK 11195 or 6 nM [3H]Ro5-4864. Assays were terminated by vacuum-assisted filtration through Schleicher and Schuell #32 glass filters which had been treated for 30min in 0.3% polyethyleneimine [28] . The filters were washed 3 x with 5ml of 50mM Tris-C1, pH 7.4.
Nonspecific binding was determined in the presence of 10txM unlabeled PK 11195. When dry, filters were placed in 5ml Bio-Safe II scintillant, and assayed for tritium by liquid scintillation spectroscopy.
Purified nuclei preparation
Monolayers of U251 cells were pulsed with 0.5 microCuries/ml [3H]thymidine for four hours then chased with media five hours prior to fractionation. PBBS in adjacent wells of U251 cells were covalently labeled with the photoaffinity agent [3H]PK 14105 as described previously [29] . Cells were scraped, homogenized, layered over 3 ml of 2.2M sucrose [30] , and centrifuged at 40,000g for 3 hours. Fractions, 250 uL each, were collected from the top of the cushion using a Buchler gradient collector.
Results
Various groups have suggested that PBBS are localized to mitochondria [17, 18] , plasma membrane [19, 22] or nuclei [5, 21, 22] . The enrichment of markers for these components was compared to the enrichment of [3H]PK 11195 binding in each of six subcellular fractions (Fig. 1) . The enrichment was calculated by dividing a marker's specific activity in the fraction of interest by the specific activity of the marker in the homogenate fraction. The enrichment of [3H]PK 11195 binding correlated best with the enrichment of the mitochondrial markers monoamine oxidase and succinate dehydrogenase.
It was not possible to obtain a single fraction to which PK 11195 binding was unique. The correlation between the specific activity of PK 11195 binding and succinate dehydrogenase activity in all fractions of 3 experiments was near unity (r = 0.95, p < 0.001) (Fig. 2) . The specific activity of PK 11195 also correlated with the specific activity of monoamine oxidase (r = 0.93, p < 0.001) ( Table  1) . No correlation was observed between PK 11195 binding and alkaline phosphatase activity (Table  1) .
A positive albeit weak correlation was observed between PK 11195 binding and the presence of DNA (Table 1) . To determine whether glioma cell nuclei contained PBBS, homogenized U251 cells which had been prelabeled with either [3H]thymidine or [3H]PK 14105, a covalent photoaffinity label for the PBBS, were centrifuged over a 2.2M sucrose cushion. Greater than 90% of the [3H]PK 14105 was recovered from the top of the cushion while more than 90% of the [3H]thymidine was recovered in the pellet (Fig. 3) (Fig. 4) . Control experiments were performed using rat C6 glioma cells. In these cells, binding of both [3H]PK 11195 and [3H]Ro5-4864 were largely displaceable by unlabeled PBBS ligands (Fig. 4) .
Discussion
PBBS are more abundant in a number of tumors than in the normal tissue from which the tumors were derived [3, 4] . The recent demonstration that ligands which bind to PBBS are capable of modulating mitochondrial respiration in rat kidney raises the question of whether PBBS modulate tumor cell respiration [16] . Indeed tumor cells have different energy requirements than normal cells [31, 32] . Furthermore, these requirements must be met by fewer mitochondria per cell than in normal tissues [31] . The first step in determining whether PBBS play a role in tumor cell mitochondrial respiration is to determine whether or not the binding site is present on the organelle.
Although convincing evidence suggests that PBBS are localized to mitochondria in rat adrenal [18] and kidney [17] , this finding cannot be generalized to other tissues or species. Human erythrocytes, which lack mitochondria [33] , exhibit a PK 11195 binding site which is pharmacologically indistinguishable from rat adrenal PBBS [19] .
The results presented in this paper support the hypothesis that PBBS are located primarily on mitochondria in human glioma cells. PK 11195 binding correlated with mitochondrial enzyme recovery while no correlation was observed between PK 11195 binding and the plasma membrane marker alkaline phosphatase. Although there was a modest correlation between DNA content of fractions and the recovery of PK 11195 binding, these two markers could be separated by centrifugation of nuclei through a 2.2 M sucrose cushion. It is impossible to rule out the presence of a small population of non-mitochondrial PBBS due to the difficulty in obtaining contaminant-free fractions of individual organelles.
The localization of PBBS to mitochondria of glioma cells may have implications in the areas of tumor bioenergetics, glioma imaging and the development of new antitumor strategies. The effects of PBBS ligands on tumor cell growth and differentiation might be explained by an action such as the modulation of cellular respiration. Indeed, nanomolar concentrations of PK 11195 and Ro5-4864 suppress oxygen consumption in mouse C 1300 neuroblastoma cells [15] . The relative abundance of high affinity PBBS on mitochondria of tumor cells encourages consideration of PBBS ligands as carriers of radioisotopes or cytotoxic agents to the interior of tumor cells. The fact that drugs must pass through the plasma membrane to reach equilibrium with mitochondrial receptors limits the size and chemical composition of agents that might be linked to PBBS ligands.
This study also demonstrates that mitochondrial PBBS in U251 cells fail to bind [3H]Ro5-4864 even in the absence of a plasma membrane barrier or cytoplasmic components. This finding supports the hypothesis that interspecies or intertissue differences in the ability of PBBS to bind Ro5-4864 are due to differences at the binding site rather than differential drug uptake, drug metabolism, or the presence of endogenous inhibitors of the Ro5-4864 domain [23] .
